Annual report pursuant to Section 13 and 15(d)

SPONSORED RESEARCH AND LICENSE AGREEMENTS AND GOVERNMENT CONTRACT (Details)

v3.24.0.1
SPONSORED RESEARCH AND LICENSE AGREEMENTS AND GOVERNMENT CONTRACT (Details)
$ in Thousands
1 Months Ended 12 Months Ended 36 Months Ended
Dec. 31, 2023
USD ($)
Aug. 31, 2023
USD ($)
Jan. 31, 2023
USD ($)
Feb. 28, 2021
USD ($)
Jan. 31, 2021
USD ($)
Feb. 29, 2020
USD ($)
Oct. 31, 2019
USD ($)
Jan. 31, 2019
USD ($)
Oct. 31, 2018
USD ($)
Dec. 31, 2023
USD ($)
agreement
period
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2023
USD ($)
Jan. 31, 2024
USD ($)
Collaborations                            
Right to opt out of agreement, different specified times | period                   2        
Upfront payment received                       $ 125,000    
Financing liability with accreted interest expense                     $ 46,200      
Accretion expense                   $ 700 2,800      
Payment of cost share to collaboration partner                   2,632 15,116      
Accounts receivable $ 30,550                 30,550 40,320   $ 30,550  
Research and development                   24,522 60,272 65,237    
Intangible asset 13,878                 13,878 14,949   13,878  
Accounts payable 7,142                 7,142 22,508   7,142  
Amortization of intangible assets                   1,100 100      
Collaborative arrangement                            
Collaborations                            
Contingent payments                   1,300,000        
License agreement with unrelated third party                            
Collaborations                            
Revenue recognized                       4,000    
Proceeds from license fees received       $ 4,000                    
One-time fee received from license rights granted       $ 4,000                    
Specified Development Events | Collaborative arrangement                            
Collaborations                            
Contingent payments                   279,500        
Specified Regulatory Events | Collaborative arrangement                            
Collaborations                            
Contingent payments                   263,100        
Specified Product Launch Events | Collaborative arrangement                            
Collaborations                            
Contingent payments                   796,000        
Development and regulatory milestones by non-CNS disease products                            
Collaborations                            
Contingent payments                   330,000        
Development and regulatory milestones by non-CNS disease products | Milestone payments on a product-by-product basis                            
Collaborations                            
Contingent payments                   100,000        
Development and regulatory milestones by CNS disease products                            
Collaborations                            
Contingent payments                   255,000        
Development and regulatory milestones by CNS disease products | Milestone payments on a product-by-product basis                            
Collaborations                            
Contingent payments                   150,000        
Delivery of drug supply for commercialization                            
Collaborations                            
Revenue recognized                     200      
Grifols                            
Collaborations                            
Upfront payment received               $ 30,000            
Deferred revenue 0                 0     0  
Grifols | Delivery of drug supply for commercialization                            
Collaborations                            
Revenue recognized                   5,600 1,600 2,000    
Grifols | Commercial milestones                            
Collaborations                            
Contingent payments               $ 297,500            
Kissei                            
Collaborations                            
Contingent payments                 $ 147,000          
Upfront payment received                 33,000          
Revenue, remaining performance obligation                 $ 33,000          
Revenue recognized                   $ 2,200 2,600 300    
Medison | Commercial and license agreements                            
Collaborations                            
Number of agreements | agreement                   2        
Knight | Commercial and license agreements                            
Collaborations                            
Upfront payment received                     2,000      
Revenue recognized                     2,000      
Knight | Minimum | Commercial and license agreements                            
Collaborations                            
Royalty payment as a percentage of net sales                   20.00%        
Knight | Maximum | Commercial and license agreements                            
Collaborations                            
Contingent payments                     20,000      
Royalty payment as a percentage of net sales                   30.00%        
Daiichi Sankyo | Collaborative arrangement                            
Collaborations                            
Revenue recognized                       1,800    
Forma                            
Collaborations                            
Upfront fee                     2,000      
Research and development                     2,000      
Forma | Commercial milestones                            
Collaborations                            
Potential payments                     165,500      
Forma | Development and regulatory milestones                            
Collaborations                            
Potential payments                     67,500      
Forma | Achievement of certain near-term regulatory milestone.                            
Collaborations                            
Research and development                     2,500      
fostamatinib                            
Collaborations                            
Revenue recognized                   $ 1,000 4,500 10,500 16,000  
fostamatinib | Maximum                            
Collaborations                            
Government contract         $ 16,500                  
fostamatinib | Grifols                            
Collaborations                            
Collaborative payment received           $ 20,000                
fostamatinib | Grifols | Upon EMA approval of fostamatinib for treatment of chronic ITP                            
Collaborations                            
Collaborative payment received           17,500                
fostamatinib | Grifols | Creditable advance royalty payment                            
Collaborations                            
Collaborative payment received           $ 2,500                
fostamatinib | Grifols | Maximum                            
Collaborations                            
Royalty payment as a percentage of net sales                   30.00%        
fostamatinib | Kissei                            
Collaborations                            
Revenue recognized     $ 20,000             $ 5,000        
Deferred revenue 1,400                 1,400 1,400   1,400  
Collaborative payment received                   5,000        
Accounts receivable 20,000                 20,000     20,000  
fostamatinib | Medison                            
Collaborations                            
Revenue recognized                   500        
fostamatinib | Medison | Financing arrangement                            
Collaborations                            
Upfront payment received             $ 5,000              
Financing component liability 0                 0 0   0  
Revenue recognized                     5,700      
fostamatinib | Medison | Achievement of milestones                            
Collaborations                            
Revenue recognized                       100    
fostamatinib | BARDA                            
Collaborations                            
Revenue recognized                   $ 100        
fostamatinib | BARDA | Maximum                            
Collaborations                            
Potential payments   $ 800                        
R552                            
Collaborations                            
Company's percentage of development costs                   20.00%        
Financing component liability 57,900                 $ 57,900     57,900  
Financing liability interest accretion discount rate                   6.40%        
Financing liability with accreted interest expense 43,600                 $ 43,600     43,600  
Development costs due to collaboration partner 800                 800     800  
Payment of cost share to collaboration partner                   $ 18,600        
Revenue, remaining performance obligation                       67,100    
R552 | Amended Lilly Agreement                            
Collaborations                            
Agreement opt-out right, exercise period                   30 days        
Funding commitment 22,600                 $ 22,600     22,600  
R552 | Maximum                            
Collaborations                            
Funding commitment 65,000                 65,000     65,000  
Non-CNS penetrant IP                            
Collaborations                            
Revenue recognized                       60,400    
Non-CNS penetrant IP | Licensed Rights                            
Collaborations                            
Revenue, remaining performance obligation                       6,700    
CNS penetrant IP                            
Collaborations                            
Revenue recognized                     500 6,200    
Research and development services | Grifols                            
Collaborations                            
Revenue recognized                     700 $ 900    
Royalty | Grifols                            
Collaborations                            
Revenue recognized                   3,200 700      
REZLIDHIA | Strategic collaboration agreement with MD Anderson                            
Collaborations                            
Development costs due to collaboration partner 15,000                 $ 15,000     $ 15,000  
Payment of cost share to collaboration partner $ 2,000                          
Collaboration period                   5 years        
REZLIDHIA | Strategic collaboration agreement with CONNECT                            
Collaborations                            
Collaboration period                   4 years        
REZLIDHIA | FDA approval and first commercial sale of product                            
Collaborations                            
Accounts payable                     15,000      
REZLIDHIA | Forma                            
Collaborations                            
Amortization of intangible assets                   $ 1,100 100      
Royalty expense                   $ 1,600 $ 100      
Subsequent event | REZLIDHIA | Strategic collaboration agreement with CONNECT                            
Collaborations                            
Development costs due to collaboration partner                           $ 3,000